Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14498503 | 0.79 | POLB (0.30) | — | |
| SCHEMBL20347452 | 0.77 | HSD11B1 (0.31) | — | |
| SCHEMBL785938 | 0.76 | POLB (0.33) | — | |
| SCHEMBL26983602 | 0.72 | PTPN1 (0.31) | — | |
| SCHEMBL19965585 | 0.71 | POLB (0.31) | — | |
| SCHEMBL30727059 | 0.70 | LMNA (0.37) | — | |
| SCHEMBL22578076 | 0.70 | — | — | |
| SCHEMBL16370866 | 0.69 | CYP2C19 (0.39) | — | |
| SCHEMBL31012850 | 0.69 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL4774211 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210284627-A1 | INDOLE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2021-09-16 | — | — | US | disclosed |
| US-20210284627-A1 | INDOLE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2021-09-16 | — | — | US | disclosed |
| EP-3766877-A1 | INDOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 2021-01-20 | — | — | EP | disclosed |
| EP-3766877-A1 | INDOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 2021-01-20 | — | — | EP | disclosed |
| US-20200255408-A1 | INDOLE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2020-08-13 | — | — | US | disclosed |
| US-20200255408-A1 | INDOLE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2020-08-13 | — | — | US | disclosed |
| US-20180362506-A1 | INDOLE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2018-12-20 | — | — | US | disclosed |
| US-20170267662-A1 | INDOLE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2017-09-21 | — | — | US | disclosed |
| US-20170267662-A1 | INDOLE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2017-09-21 | — | — | US | disclosed |
| US-20170267662-A1 | INDOLE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2017-09-21 | — | — | US | disclosed |
| US-20130116240-A1 | INDOLE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2013-05-09 | — | — | US | disclosed |
| US-8299070-B2 | Indole compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299070-B2 | Indole compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299070-B2 | Indole compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2012-10-30 | — | — | US | disclosed |
| EP-2505586-A1 | INDOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2012-10-03 | — | — | EP | disclosed |
| EP-2505586-A1 | INDOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2012-10-03 | — | — | EP | disclosed |
| US-20110306599-A1 | INDOLE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2011-12-15 | — | — | US | disclosed |
| US-20110306599-A1 | INDOLE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2011-12-15 | — | — | US | disclosed |
| US-20110306599-A1 | INDOLE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2011-12-15 | — | — | US | disclosed |
| WO-2011065402-A1 | INDOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | 日本たばこ産業株式会社 (JP) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255408-A1 | INDOLE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | IDO1, IDO2, INMT | METAP2 476/4885 |
| US-20180362506-A1 | INDOLE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | IDO1, IDO2, INMT | METAP2 476/4885 |
| US-20130116240-A1 | INDOLE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | IDO1, IDO2, INMT | METAP2 476/4885 |
| US-20170267662-A1 | INDOLE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | IDO1, IDO2, INMT | METAP2 843/4885 |
| US-20210284627-A1 | INDOLE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | IDO1, IDO2, INMT | METAP2 476/4885 |
| US-20110306599-A1 | INDOLE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | IDO1, IDO2, INMT | METAP2 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.